China-based rare disease specialist Sperogenix Therapeutics Limited has entered into a partnership with compatriot firm LUCA Healthcare Limited Co., a company specializing in digital targeting and healthcare solutions, to bolster the application of digital therapy in myasthenia gravis. The collaboration aims to enhance the use of digital therapy in treating this rare disease, with no financial details disclosed.
Focusing on Technology Development and Clinical Practice
The cooperation will leverage the resources and experience of both Sperogenix Therapeutics and LUCA Healthcare in technology development, clinical design and operation, and clinical practice. The partnership will focus on verifying the safety and effectiveness of digital therapy in clinical trials and jointly promoting the development process and application of digital therapy in China.
Rigorous Medical Logic and Data Processing
Both companies will employ a comprehensive set of data processing and algorithm development processes based on rigorous medical logic to address relevant challenges. By evaluating the technical feasibility and accessibility, they aim to improve the accuracy of the in-depth learning model in evaluating the symptoms of myasthenia gravis patients. This approach will provide a more precise assessment tool, potentially leading to better patient outcomes and improved quality of life for those affected by the disease.-Fineline Info & Tech
